Ablynx NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ablynx NV Elects New Chairman Of Board
Ablynx NV announced that it is the intention of the Board to separate the roles of Chairman and CEO. The Board intends to elect Dr Fellner as Chairman to succeed Dr Moses who will remain Chief Executive Officer. The Company also announced that it is the intention of Dr Stephen Bunting and Mr Denis Lucquin to resign from the Ablynx Board.
Latest Developments for Ablynx NV
- Ablynx NV to Present Pre-Clinical Proof-of-Concept Data on ALX-0761 at ACR
- Ablynx NV Updates on Phase II Part of Combined Phase I/II Study of Anti-IL-6R Nanobody, ALX-0061 Results
- Ablynx NV Updates on Results of Phase I/II Study with Anti-Il-6R Nanobody, ALX-0061, in Rheumatoid Arthritis Patients
- Ablynx NV Announces New Compelling Results On Ozoralizumab (ATN-103) In Rheumatoid Arthritis
Latest Key Developments in Biotechnology
- Avita Medical Ltd announces senior management changes
- PDL BioPharma Inc gives Q4 2013 guidance in line with analysts' estimates
- Lorus Therapeutics Inc completes $7,001,500 prospectus offering of common shares
- KaloBios Pharmaceuticals Inc announces preliminary phase 1 results in advanced hematologic malignancies with kb004, an anti-epha3 monoclonal antibody
- Share this
- Digg this